112 related articles for article (PubMed ID: 32924641)
1. The pH-triggered polyglutamate brush co-delivery of MDR1 and survivin-targeting siRNAs efficiently overcomes multi-drug resistance of NSCLC.
Wang Z; Liang Y; Liu Y; Xia H; Liu J; Jin X; Li Z
Drug Dev Ind Pharm; 2020 Nov; 46(11):1862-1872. PubMed ID: 32924641
[TBL] [Abstract][Full Text] [Related]
2. Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin.
Wang Z; Zou H; Wang Z; Wu J; Xia Z; Feng M
Int J Pharm; 2016 May; 505(1-2):24-34. PubMed ID: 27039150
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
5. Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC.
Chen L; Wang S; Liu Q; Zhang Z; Lin S; Zheng Q; Cheng M; Li Y; Cheng C
Colloids Surf B Biointerfaces; 2020 Sep; 193():111105. PubMed ID: 32417465
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
7. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
8. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
10. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
[TBL] [Abstract][Full Text] [Related]
11. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
12. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
[TBL] [Abstract][Full Text] [Related]
13. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
Kara G; Parlar A; Cakmak MC; Cokol M; Denkbas EB; Bakan F
Colloids Surf B Biointerfaces; 2020 Dec; 196():111340. PubMed ID: 32956996
[TBL] [Abstract][Full Text] [Related]
14. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
15. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
17. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
19. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells.
He Y; Bi Y; Hua Y; Liu D; Wen S; Wang Q; Li M; Zhu J; Lin T; He D; Li X; Wang Z; Wei G
J Exp Clin Cancer Res; 2011 Oct; 30(1):104. PubMed ID: 22035293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
